Infinity Pharmaceuticals, Inc. INFIQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 12.48% | 6.71% | 1.97% | -5.84% | -- |
| Total Depreciation and Amortization | -11.20% | -8.30% | -4.58% | -1.46% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.96% | 44.50% | 29.18% | 27.49% | -- |
| Change in Net Operating Assets | -167.39% | -176.58% | -146.93% | -71.89% | -- |
| Cash from Operations | 6.78% | -1.94% | -4.46% | -9.74% | -- |
| Capital Expenditure | 100.00% | 100.00% | -54.55% | -70.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 199.65% | 199.73% | -100.69% | -100.17% | -- |
| Cash from Investing | 199.39% | 199.53% | -101.00% | -100.24% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.44% | -92.49% | -99.92% | -99.55% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.44% | -92.49% | -99.92% | -99.55% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.53% | 49.08% | -181.60% | -160.09% | -- |